Novartis discontinues development of VHB937 in ALS
Novartis AG discontinued development of VHB937 in amyotrophic lateral sclerosis (ALS).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novartis discontinues Phase 2 ALS trial after failed endpoints
Novartis said its Phase 2 ALS treatment VHB937 did not meet primary or secondary endpoints and the company will discontinue development.